By a nose: Peninsula company moves from nasal devices to drugs with latest approval
Intersect ENT Inc. won Food and Drug Administration approval for a sinus implant that delivers an anti-inflammatory steroid to treat nasal polyps.
It isn't the Menlo Park company's (NASDAQ: XENT) first product to be greenlighted by regulators — Intersect's previous three products were medical devices — but it is the first to be approved as a drug.
Sinuva is placed within a sinus implant, which is put in during a routine visit to a docto r's office. It expands into the sinus cavity and delivers…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Food and Drug Administration (FDA) | Health Management | Medical Devices | Men | Polyps